Novo Nordisk
Novo Nordisk CEO and Board Leadership Step Down Amid Market Pressures; New Board to Prioritize Faster Decision-Making
Novo Nordisk; CEO resignation; Lars Fruergaard Jørgensen; board leadership change; Novo Nordisk Foundation; share price decline; strategic decision-making; competition; Lars Rebien Sørensen; executive transition
Novo throws weight behind budding rare disease pipeline
Novo Nordisk; rare disease; pipeline; Omeros; Zaltenibart; MASP-3 inhibitor; PNH; complement system; milestone payments
Cuts Continue as Novo Nordisk Restructuring Moves Forward
Novo Nordisk; Restructuring; Job Cuts; Pharmaceutical Industry
Novo Nordisk Acquires Rights to Omeros’ MASP-3 Inhibitor Zaltenibart
Novo Nordisk; Omeros; Zaltenibart; MASP-3 Inhibitor; Rare Blood and Kidney Disorders
Novo Nordisk Ends Cell Therapy Research Amid Major Restructuring
Novo Nordisk; cell therapy; restructuring; job cuts; diabetes; cost-cutting; R&D strategy; biotech; obesity; partnership cancellations
High-Dose Wegovy Demonstrates Enhanced Weight Loss in Phase III Trial
Wegovy, semaglutide, obesity treatment, weight loss, Novo Nordisk, Phase III trial, STEP UP trial
EU Panel Recommends Wegovy for Preventing Cardiac Events, Following FDA Lead
Wegovy, EU panel, FDA, cardiac events, weight loss, Novo Nordisk